VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | Emerging management options for AML

Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, shares his thoughts on the evolving therapeutic landscape of acute myeloid leukemia (AML) and what we are likely to see in the future. This includes the incorporation of novel agents, alone and in combination, into standard-of-care backbones, and replacing intensive chemotherapy for all patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter